AIM ImmunoTech Advances Ampligen Toward Potential Pivotal Development
OCALA, Fla., June 24, 2026 AIM ImmunoTech Inc. highlighted significant progress across its pancreatic cancer development program, positioning Ampligen®...
Phase 2
Advertisement
Tenaya Gene Therapy Shows Strong Arrhythmia Reduction in ARVC Trial
SOUTH SAN FRANCISCO, Calif., May 15, 2026 Tenaya Therapeutics reported encouraging interim Phase 1b/2 clinical data for TN-401, its...
Ascidian Therapeutics Advances ACDN-01 in Stargardt Trial
BOSTON, MASSACHUSETTS, May 04, 2026 Ascidian Therapeutics has announced the completion of the adult dose escalation phase in its...
Bambusa Therapeutics Completes BBT001 Trial Enrollment
BOSTON, MASSACHUSETTS, April 30, 2026 Bambusa Therapeutics has announced the successful completion of patient enrollment in its Phase 1b/2a...
Alkermes Reports Strong Phase 2 Data for Narcolepsy Drug
DUBLIN, April 16, 2026 Alkermes plc has announced new data from its Vibrance-1 Phase 2 clinical study of alixorexton,...
Advertisements
MAIA Activates U.S. Site for Phase 2 Lung Cancer Trial
CHICAGO, April 16, 2026 MAIA Biotechnology, Inc. has announced the activation of its first U.S. clinical site for the...
XellSmart Advances Phase 2 Parkinson’s Cell Therapy Trial
Suzhou, China | April 14, 2026 XellSmart has announced the initiation of a multicenter Phase II clinical trial evaluating...
Hoth HT-001 Meets Endpoint, Expands Phase 2 Trial in EU
NEW YORK, USA — April 1, 2026 Hoth Therapeutics, Inc. announced that its investigational therapy HT-001 has successfully met...
Anixa Advances Breast Cancer Vaccine to Phase 2 Trial
SAN JOSE, Calif., USA — April 1, 2026 In a significant advancement in cancer immunotherapy and clinical-stage biotechnology innovation,...
Advertisement
